


Fosamprenavir

Cat. No.:	HY-78726		
CAS No.:	226700-79-4		
Molecular Formula:	C ₂₅ H ₃₆ N ₃ O ₉ PS		
Molecular Weight:	585.61		
Target:	HIV; Endogenous Metabolite		
Pathway:	Anti-infection; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (170.76 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.7076 mL	8.5381 mL	17.0762 mL
	5 mM	0.3415 mL	1.7076 mL	3.4152 mL
	10 mM	0.1708 mL	0.8538 mL	1.7076 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Fosamprenavir (Amprenavir phosphate;GW 433908) is a phosphate ester proagent of the antiretroviral protease inhibitor Amprenavir, with improved solubility^[1]. Anti-HIV infection^[1].

IC₅₀ & Target

HIV^[1]

CUSTOMER VALIDATION

- Nat Commun. 2020 Sep 4;11(1):4417.
- Int J Antimicrob Agents. 2019 Dec;54(6):814-819.
- Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00872-20.
- Research Square Print. 2022 May.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Falcoz C, et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA